VERACYTE, INC. Restricted Cash and Cash Equivalents
VERACYTE, INC. (VCYT) had Restricted Cash and Cash Equivalents of $1.67 million as of 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Balance Sheet › Assets › Restricted Cash and Cash Equivalent
us-gaap:RestrictedCashAndCashEquivalents · last filed 2026-07-31
- 2026-06-30: Restricted Cash and Cash Equivalents $1.67M.
- 2026-03-31: Restricted Cash and Cash Equivalents $1.66M.
- 2025-12-31: Restricted Cash and Cash Equivalents $1.65M.
- 2025-09-30: Restricted Cash and Cash Equivalents $1.64M.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2026-06-30 | $1.67M 10-Q · filed 2026-07-31 |
| 2026-03-31 | $1.66M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $1.65M 10-Q · filed 2026-07-31 |
| 2025-09-30 | $1.64M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $1.65M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $1.65M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $1.54M 10-Q · filed 2025-11-05 |
| 2024-09-30 | $1.08M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $1.09M 10-Q · filed 2024-08-07 |
| 2023-12-31 | $876.00K 10-Q · filed 2024-11-07 |
| 2014-06-30 | $118.00K 10-Q · filed 2014-08-14 |
| 2014-03-31 | $118.00K 10-Q · filed 2014-05-09 |
| 2013-12-31 | $118.00K 10-Q · filed 2014-08-14 |
| 2013-09-30 | $118.00K 10-Q · filed 2013-11-25 |
| 2012-12-31 | $168.00K 10-K · filed 2014-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| BIODESIX INC (BDSX) | United States | $0.312B |